All articles by Swagath Bandhakavi
Swagath Bandhakavi
GC Cell and Lukas Biomedical forge global partnership to advance cell therapy
The collaboration between GC Cell and Lukas Biomedical aims to improve awareness and access to autologous T cell therapy by utilising their combined expertise in cell treatment
Exscientia to take full control of CDK7 inhibitor programme with acquisition of GT Apeiron’s stake
The decision to secure full control aligns with the upcoming Phase 1 dose escalation data readout of the CDK7 inhibitor
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR)
Rona Therapeutics closes $35m funding round to advance siRNA programmes
Based in China, Rona Therapeutics specialises in treatments for metabolic diseases and CNS degenerative diseases
CSL Behring’s Hemgenix administered to first haemophilia B patients in Europe
Last year, the European Commission granted conditional marketing authorisation for Hemgenix to treat severe and moderately severe haemophilia B in adults without a history of Factor IX inhibitors
Ascentage Pharma announces closing of $75m equity investment by Takeda
Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death
C-Path and Centogene partner to advance drug development for lysosomal diseases
The partnership aims to leverage the strengths of both organisations in genetic and real-world data to address challenges in developing safe and effective treatments for LDs
Gilead’s lenacapavir meets key efficacy endpoints of superiority in Phase 3 HIV trial
According to topline results from an interim analysis, the twice-yearly injectable HIV-1 capsid inhibitor achieved 100% efficacy in its investigational use
Dizal gains Chinese approval for golidocitinib in relapsed or refractory PTCL
The NMPA approval was driven by the findings of the JACKPOT8 Part B study in which golidocitinib monotherapy demonstrated superior and durable antitumour efficacy compared to existing treatment options
GenFleet receives IND approval from China’s NMPA for GFH375
G12D mutation is the most prevalent KRAS mutation detected in human cancers, and no G12D-targeted therapies have been approved yet